Skip to main content

Table 3 The number of patients demonstrating a metabolic response following 14 and 28 days of treatment

From: Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma

 

After 14 days

After 28 days

 

Metabolic response

Metabolic progress

Metabolic response

Metabolic progress

SULpeaka

9/28

8/28

11/28

4/28

SUVmax

8/32

5/32

12/30

6/30

TLG2.5

14/32

6/32

14/30

6/30

TLG50

15/32

3/32

12/30

5/30

HottestSULpeaka

9/28

7/28

10/28

5/28

HottestSUVmax

8/32

4/32

8/30

4/30

HottestTLG2.5

14/32

6/32

14/30

6/30

HottestTLG50

17/32

5/32

15/30

6/30

  1. aAssessed according to PERCIST1.0. Only 28 patients had a lesion that fulfilled the PERCIST criteria.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us